The FDA has approved nivolumab plus platinum-doublet chemotherapy for patients with non-small cell lung cancer in the neoadjuvant setting. Nivolumab is the first immune checkpoint inhibitor to get approval for resectable NSCLC….
Tag: Lung Cancer Treatment
Adenocarcinoma Lung Cancer: Symptoms and Treatment
There are two predominant types of lung cancer: small cell lung cancer and non-small cell lung cancer. NSCLC accounts for about 80% to 85% of all lung cancers. Adenocarcinoma is a type…
European Commission Approves Pfizer’s Lorviqua for Advanced Lung Cancer Treatment
European Commission (EC) has granted marketing authorization for Lorviqua as monotherapy for treatment of patients with anaplastic lymphoma kinase (ALK) – positive advanced non-small cell lung cancer. Lorviqua is approved in US…
Sugemalimab with Chemo Demonstrates Improvement in NSCLC Survival Rates
In the year 2020, an estimate of 2.2 million people has been diagnosed with lung cancer. It is the second most commonly diagnosed cancer and is among leading cause of cancer deaths….
Study: Lung Cancer Screenings Associated with Death Decline
Lung cancer is one of the leading causes of cancer deaths in the United States and is diagnosed in more than 2lac people annually. According to a Mount Sinai study published in…
Lymph Nodes – Common Site of Lung Cancer Spread
One of the biggest issues that are being faced by lung cancer patients is that the cancer may spread to other parts of the body. The term used when cancer spreads to…
Healthy Habits to Follow During and After Lung Cancer Treatment
When lung cancer is diagnosed, a person goes through various mental and financial challenges. One needs to maintain a healthy lifestyle to stay well during and after lung cancer treatment. By developing…
US FDA Approves Roche’s Tecentriq as Adjuvant Treatment for Early NSCLC
The US Food and Drug Administration (FDA) has approved Roche’s Tecentriq or atezolizumab as adjuvant treatment for patients with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors express PD-L1=1%, as determined…